Fig. 7
From: Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells
Ghrelin specifically inhibited HO-8910 PM. A-B MTT assay of A2780S (A) and A2780CP (B) under ghrelin treatment (10 nM) in the presence or absence of cisplatin (1 μg/ml). C-D The BrdU incorporation by HUVEC (C), Gist-T1 and iPSC-MSC (D) under the treatment of ghrelin. E A schematic showing the effects of ghrelin sensitizing HO-8910 PM to cisplatin. * p < 0.05, ***p < 0.001